S. 2710

119th CONGRESS 1st Session

To amend title XI of the Social Security Act to require pharmaceutical and device manufacturers to publicly disclose covered payments made to patient advocacy organizations.

IN THE SENATE OF THE UNITED STATES · September 4, 2025 · Sponsor: Mr. Grassley · Committee: Committee on Finance

S. 2710
- SEC. 1. Short title
- SEC. 2. Disclosure of pharmaceutical and device manufacturer covered payments to patient advocacy organizations

SEC. 1. Short title

This Act may be cited as the Open Payments Expansion Act.

SEC. 2. Disclosure of pharmaceutical and device manufacturer covered payments to patient advocacy organizations

(a) In general
- Section 1128G of the Social Security Act () is amended— 42 U.S.C. 1320a–7h
  - (3) Donations to patient advocacy organizations
    - (A) In general
      - In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, details regarding any covered payment made by such manufacturer or organization to any patient advocacy organization, including—
        
        (i) the name of the patient advocacy organization; and
        
        (ii) the amount of the covered payment.
    - (B) Definitions
      - In this paragraph:
        
        (i) The term covered payment means any—
        
        payment or other transfer of value; or
        
        indirect payment or other transfer of value.
        
        (ii) The term indirect payment or other transfer of value means a payment or other transfer of value made by an applicable manufacturer or applicable group purchasing organization to a patient advocacy organization through a third party, where the applicable manufacturer or applicable group purchasing organization requires, instructs, directs, or otherwise causes the third party to provide the payment or transfer of value, in whole or in part, to a patient advocacy organization.
        
        Indirect payment or other transfer of value
        
        (iii) The term patient advocacy organization means an organization described in of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code that— section 501(c)(3)
        
        Patient advocacy organization
        
        provides education, advocacy, and support services oriented towards patients and caregivers;
        
        is concerned with a medical condition diagnosed by a licensed medical practitioner who is in good standing with a State licensing body; or
        
        has a mission that seeks to help vulnerable individuals affected by medical conditions or to help the families of such vulnerable individuals and takes actions consistent with such mission.
  - in subsection (a), by adding at the end the following new paragraph:
  - in subsection (c)(1)(C)(ix), by striking each place it appears and inserting covered recipient, or patient advocacy organization.
(b) Administration
- of title 44, United States Code, shall not apply to this section or the amendments made by this section. Chapter 35

S. 2710

Table of contents

SEC. 1. Short title

SEC. 2. Disclosure of pharmaceutical and device manufacturer covered payments to patient advocacy organizations